Bisphosphonates still sub-optimal
From Dr Eamonn Brankin
The story 'Bisphosphonates best given weekly' (News,
20 July) references a study on which I was the lead author, 'The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases', published in the July issue of Current Medical Research and Opinion.
The study set out to examine the impact of dosing frequency on compliance and persistence with bisphosphonates in the UK and demonstrated that a less frequent dosing regimen significantly improved levels of both compliance and persistence.
The study was not intended or designed to determine the comparative benefits of treatment with a daily and weekly bisphosphonate. This comparison was simply the methodology used to evaluate the study hypothesis.
Indeed, rather than suggesting that weekly bisphosphonates are a 'treatment of choice', a key conclusion is that even on a weekly regimen, bisphosphonate usage remains a sub-optimal therapy.